Connor Clark & Lunn Investment Management Ltd. Has $3.15 Million Holdings in Health Catalyst, Inc. $HCAT

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 172.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 694,361 shares of the company's stock after acquiring an additional 439,599 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.99% of Health Catalyst worth $3,145,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Group One Trading LLC raised its holdings in Health Catalyst by 107.6% during the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after buying an additional 2,260 shares in the last quarter. Aquatic Capital Management LLC acquired a new position in shares of Health Catalyst during the 4th quarter valued at about $63,000. XTX Topco Ltd acquired a new position in shares of Health Catalyst during the 1st quarter valued at about $54,000. Brevan Howard Capital Management LP acquired a new position in shares of Health Catalyst during the 4th quarter valued at about $92,000. Finally, Jump Financial LLC acquired a new position in shares of Health Catalyst during the 4th quarter valued at about $112,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on HCAT shares. Citigroup lowered Health Catalyst from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $6.50 to $3.50 in a report on Friday, August 8th. Cantor Fitzgerald reissued a "neutral" rating and set a $4.00 price objective (down previously from $9.00) on shares of Health Catalyst in a report on Friday, August 8th. Canaccord Genuity Group lowered their price objective on Health Catalyst from $10.00 to $9.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus dropped their price objective on Health Catalyst from $5.50 to $4.50 and set a "hold" rating on the stock in a research note on Friday, August 8th. Finally, BTIG Research lowered Health Catalyst from a "buy" rating to a "neutral" rating in a research note on Tuesday, June 17th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $6.18.

Health Catalyst Stock Performance

Shares of NASDAQ:HCAT traded up $0.10 during trading on Monday, hitting $3.02. 377,962 shares of the stock were exchanged, compared to its average volume of 706,998. Health Catalyst, Inc. has a 1-year low of $2.52 and a 1-year high of $9.24. The company has a market capitalization of $212.17 million, a price-to-earnings ratio of -2.00 and a beta of 1.46. The company's fifty day simple moving average is $3.74 and its 200-day simple moving average is $4.15. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.